Effect of insulin and an erythropoietin-derived peptide (ARA290) on established neuritic dystrophy and neuronopathy in Akita (Ins2 Akita) diabetic mouse sympathetic ganglia

Experimental Neurology

Volumn 232, Issue 2, 2011, Pages 126-135

  Schmidt, Robert E ^a   Feng, Dongyan ^a   Wang, Qiuling ^a   Green, Karen G ^a   Snipes, Lisa L ^a   Yamin, Michael ^b   Brines, Michael ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ARAIM PHARMACEUTICALS   (United States)

Author keywords

Akita mouse; Diabetes; Erythropoietin; Insulin; Neuritic dystrophy; Neuronopathy; Sympathetic ganglia

Indexed keywords

ARA 290; ERYTHROPOIETIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTONOMIC NEUROPATHY; BODY WEIGHT; CELIAC GANGLION; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DISEASE SEVERITY; GLUCOSE BLOOD LEVEL; INSULIN TREATMENT; MALE; MOUSE; NERVE CELL DEGENERATION; NONHUMAN; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SYMPATHETIC GANGLION; SYMPATHETIC NERVE CELL;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 1; DIABETIC NEUROPATHIES; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN; GANGLIA, SYMPATHETIC; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MICROSCOPY, ELECTRON; NERVE DEGENERATION; NEURITES; PEPTIDES;

EID: 80054977417     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.05.025     Document Type: Article

References (80)

1. Ballman M., Conlon J.M. Changes in the somatostatin, substance P and vasoactive intestinal polypeptide content of the gastrointestinal tract following streptozotocin induced diabetes in the rat. Diabetologia 1985, 28:355-358.
2. Belai A., Burnstock G. Selective damage of intrinsic calcitonin gene-related peptide-like immunoreactive enteric nerve fibers in streptozotocin-induced diabetic rats. Gastroenterology 1987, 92:730-734.
3. Baloh R.H. Mitochondrial dynamics and peripheral neuropathy. Neuroscientist 2008, 14:12-18.
4. Baloh R.H., Schmidt R.E., Pestronk A., Milbrandt J. Altered axonal mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth disease from mitofusin 2 mutations. J. Neurosci. 2007, 27:422-430.
5. Barsoum M.J., Yuan H., Gerencser A.A., Liot G., Kushnareva Y., Graber S., Kovacs I., Lee W.D., Waggoner J., Cui J., White A.D., Bossy B., Martinou J.C., Youle R.J., Lipton S.A., Ellisman M.H., Perkins G.A., Bossy-Wetzel E. Nitric oxide-induced mitochondrial fission is regulated by dynamin-related GTPases in neurons. EMBO J. 2006, 253:900-911.
6. Bianchi R., Buyukakilli B., Brines M., Savino C., Cavaletti G., Oggioni N., Lauria G., Borgna M., Lombardi R., Cimen B., Comelekoglu U., Kanik A., Tataroglu C., Cerami A., Ghezzi P. Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:823-828.
7. Bianchi R., Gilardini A., Rodriguez-Menendez V., Oggioni N., Canta A., Colombo T., Michele G.D., Martone S., Sfacteria A., Piedemonte G., Grasso G., Beccaglia P., Ghezzi P., D'Incalci M., Lauria G., Cavaletti G. Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growth. Eur. J. Cancer 2007, 43:710-717.
8. Bosman D.R., Osborne C.A., Marsden J.T., Macdougall I.C., Gardner W.N., Watkins P.J. Erythropoietin response to hypoxia in patients with diabetic autonomic neuropathy and non-diabetic chronic renal failure. Diabet. Med. 2002, 19:65-69.
9. Bosman D.R., Winkler A.S., Marsden J.T., Macdougall I.C., Watkins P.J. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 2001, 24:495-499.
10. Brines M.L., Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat. Rev. Neurosci. 2005, 6:484-494.
11. Brines M.L., Ghezzi P., Keenan S., Agnello D., de Lanerolle N.C., Cerami C., Itri L.M., Cerami A. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:10526-10531.
12. Brines M.L., Grasso G., Fiordaliso F., Sfacteria A., Ghezzi P., Fratelli M., Latini R., Xie Q.-W., Smart J., Su-Rick C.-J., Pobre E., Diaz D., Gomez D., Hand C., Coleman T., Cerami A. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:14907-14912.
13. Brines M., Patel N.S., Villa P., Brines C., Mennini T., De Paola M., Erbayraktar Z., Erbayraktar S., Sepodes B., Thiemermann C., Ghezzi P., Yamin M., Hand C.C., Xie Q.W., Coleman T., Cerami A. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:10925-10930.
14. Brown M.R., Sullivan P.G., Geddes J.W. Synaptic mitochondria are more susceptible to Ca2+ overload than nonsynaptic mitochondria. J. Biol. Chem. 2006, 281:11658-11668.
15. Cai F., Helke C.J. Abnormal PI3 kinase/Akt signal pathway in vagal afferent neurons and vagus nerve of streptozotocin-diabetic rats. Brain Res. Mol. Brain Res. 2003, 110:234-244.
16. Cellek S., Foxwell N.A., Moncada S. Two phases of nitrergic neuropathy in streptozotocin induced diabetic rats. Diabetes 2003, 52:2353-2362.
17. Chan D.C. Mitochondria: dynamic organelles in disease, aging, and development. Cell 2006, 125:1241-1252.
18. Chang E.B., Bergenstal R.M., Field M. Diarrhea in streptozocin-treated rats. Loss of adrenergic regulation of intestinal fluid and electrolyte transport. J. Clin. Invest. 1985, 75:1666-1670.
19. Chang E.M., Fedorak R.N., Field M. Experimental diabetic diarrhea in rats. Intestinal mucosal denervation hypersensitivity and treatment with clonidine. Gastroenterology 1986, 91:564-569.
20. C96Y Akita mice. Behav. Brain Res. 2005, 157:31-38.
21. Chung S.K., Ho E.C.M., Lam K.S.L., Yamagishi S.-I., Yagihashi S., Chung S.S.M. Implications of the aldose reductase gene in peripheral nerve integrity and its environmental insults in diabetes. J. Peripher. Nerv. Syst. 2003, 8:169. (Abst.).
22. Cotroneo P., Maria Ricerca B., Todaro L., Pitocco D., Manto A., Ruotolo V., Storti S., Damiani P., Caputo S., Ghirlanda G. Blunted erythropoietin response to anemia in patients with Type 1 diabetes. Diabetes Metab. Res. Rev. 2000, 16:172-176.
23. Crawford J. Erythropoietin: high profile, high scrutiny. J. Clin. Oncol. 2007, 25:1021-1023.
24. Akita/+ mice. PLoS One 2010, 5(5):e10832. 10.1371/journal.pone.0010832.
25. Diani A.R., Grogan D.M., Yates M.E., Risinger D.L., Gerritsen G.C. Radiologic abnormalities and autonomic neuropathology in the digestive tract of the ketonuric diabetic Chinese hamster. Diabetologia 1979, 17:33-40.
26. Drueke T.B., Locatelli F., Clyne N., Eckardt K.U., Macdougall I.C., Tsakiris D., Burger H.U., Scherhag A. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N. Engl. J. Med. 2006, 355:2071-2084.
27. Duchen L.W., Anjorin A., Watkins P.J., Mackay J.D. Pathology of autonomic neuropathy in diabetes mellitus. Ann. Intern. Med. 1980, 92:301-303.
28. Fernyhough P., Chowdhury S.K.R., Schmidt R.E. Mitochondrial stress and the pathogenesis of diabetic neuropathy. Expert Rev. Endocrinol. Metab. 2010, 5:39-49.
29. Frank S. Dysregulation of mitochondrial fusion and fission: an emerging concept in neurodegeneration. Acta Neuropathol. (Berl.) 2006, 111:93-100.
30. Hall K.E., Sima A.A., Wiley J.W. Voltage-dependent calcium currents are enhanced in dorsal root ganglion neurones from the Bio Bred/Worchester diabetic rat. J. Physiol. 1995, 486(Pt 2):313-322.
31. Hand C.C., Brines M. Promises and pitfalls in erythropoietin-mediated tissue protection: are nonerythropoietic derivatives a way forward?. J. Investig. Med. 2010, doi:10.231/JIM.0b013e3181ed30bf.
32. Henke M., Mattern D., Pepe M., Bezay C., Weissenberger C., Werner M., Pajonk F. Do erythropoietin receptors on cancer cells explain unexpected clinical findings?. J. Clin. Oncol. 2006, 24:4708-4713.
33. Hoke A. Neuroprotection in the peripheral nervous system: rationale for more effective therapies. Arch. Neurol. 2006, 63:1681-1685.
34. Huang T.J., Verkhratsky A., Fernyhough P. Insulin enhances mitochondrial inner membrane potential and increases ATP levels through phosphoinositide 3-kinase in adult sensory neurons. Mol. Cell. Neurosci. 2005, 28:42-54.
35. Huang T.J., Sayers N.M., Fernyhough P., Verkhratsky A. Diabetes-induced alterations in calcium homeostasis in sensory neurones of streptozotocin-diabetic rats are restricted to lumbar ganglia and are prevented by neurotrophin-3. Diabetologia 2002, 45:560-570.
36. Izumi T., Yokota-Hashimoto H., Zhao S., Wang J., Halban P.A., Takeuchi T. Dominant negative pathogenesis by mutant proinsulin in the Akita diabetic mouse. Diabetes 2003, 52:409-416.
37. Karbowski M., Youle R.J. Dynamics of mitochondrial morphology in healthy cells and during apoptosis. Cell Death Differ. 2003, 10:870-880.
38. Keswani S.C., Buldanlioglu U., Fischer A., Reed N., Polley M., Liang H., Zhou C., Jack C., Leitz G.J., Hoke A. A novel endogenous erythropoietin mediated pathway prevents axonal degeneration. Ann. Neurol. 2004, 56:815-826.
39. Keswani S.C., Leitz G.J., Hoke A. Erythropoietin is neuroprotective in models of HIV sensory neuropathy. Neurosci. Lett. 2004, 371:102-105.
40. Knott A.B., Perkins G., Schwarzenbacher R., Bossy-Wetzel E. Mitochondrial fragmentation in neurodegeneration. Nat. Rev. Neurosci. 2008, 9:505-518.
41. Leinninger G.M., Backus C., Sastry A.M., Yi Y.B., Wang C.W., Feldman E.L. Mitochondria in DRG neurons undergo hyperglycemic mediated injury through Bim, Bax and the fission protein Drp1. Neurobiol. Dis. 2006, 23:11-22.
42. Lipton S.A. Erythropoietin for neurologic protection and diabetic neuropathy. N. Engl. J. Med. 2004, 350:2516-2517.
43. Malagelada J.-R. Ileal brake failure in streptozotocin-induced diabetic rat. Scand. J. Gastroenterol. 2004, 39:4223-4237.
44. Mathews C.E., Langley S.H., Leiter E.H. New mouse model to study islet transplantation in insulin-dependent diabetes mellitus. Transplantation 2002, 73:1333-1336.
45. Melli G., Jack C., Lambrinos G.L., Ringkamp M., Hoke A. Erythropoietin protects sensory axons against paclitaxel-induced distal degeneration. Neurobiol. Dis. 2006, 24:525-530.
46. Nishikawa T., Edelstein D., Du X.L., Yamagishi S., Matsumura T., Kaneda Y., Yorek M.A., Beebe D., Oates P.J., Hammes H.P., Giardino I., Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787-790.
47. Obrosova I.G., Stavniichuk R., Drel V.R., Shevalye H., Vareniuk I., Nadler J.L., Schmidt R.E. Different roles of 12/15-lipoxygenase in diabetic large and small fiber peripheral and autonomic neuropathies. Am. J. Pathol. 2010, 177:1436-1447.
48. Ordog T., Takayama I., Cheung W.K.T., Ward S.M., Sanders K.M. Remodeling of networks of interstitial cells of Cajal in a murine model of diabetic gastroparesis. Diabetes 2000, 49:1731-1739.
49. Ouyang A., Eggli D.F., Li Q., Ju J., Yu S. A preliminary study of gastric emptying function and peripheral nerve innervation in Ins2 Akita mice, a model of type 1 diabetes. Neurogastroenterol. Motil. 2007, 19:421.
50. Park H.-J., Zhang Y., Du C., Welzig C.M., Madias C., Aronovitz M.J., Georgescu S.P., Naggar I., Wang B., Kim Y.-B., Blaustein R.O., Karas R.H., Liao R., Mathews C.E., Galper J.B. Role of SREBP-1 in the development of parasympathetic dysfunction in the hearts of type 1 diabetic Akita mice. Circ. Res. 2009, 105:287-294.
51. Patel N.S., Villa P., Brines C., Mennini T., De Paola M., Erbayraktar Z., Erbayraktar S., Sepodes B., Thiemermann C., Ghezzi P., Yamin M., Hand C.C., Xie Q.W., Coleman T., Cerami A. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:10925-10930.
52. Rao S.V., Stamler J.S. Erythropoietin, anemia, and orthostatic hypotension: the evidence mounts. Clin. Auton. Res. 2002, 12:141-143.
53. Ricerca B.M., Todaro L., Caputo S., Cotroneo P., Damiani P., Manto A., Pitocco D., Storti S., Ghirlanda G. Blunted erythropoietin response to anemia in type 1 diabetic patients. Diabetes Care 1999, 22:647.
54. Roesler R., Quevedo J., Schroder N. Erythropoietin, glutamate, and neuroprotection. N. Engl. J. Med. 2004, 351:1465-1466. (author reply 1465-1466).
55. Ron D. Proteotoxicity in the endoplasmic reticulum: lessons from the Akita diabetic mouse. J. Clin. Invest. 2002, 109:443-445.
56. Rundles R. Diabetic neuropathy. General review with report of 125 cases. Medicine 1945, 24:111-160.
57. Saito T., Tojo K., Nishimura R., Kageyama S., Tajima N. Coefficient of variation of R-R intervals in electrocardiogram is a sensitive marker of anemia induced by autonomic neuropathy in type 1 diabetes. Diabetes Res. Clin. Pract. 2007, 78:60-64.
58. Schmidt R.E. Neuronal preservation in the sympathetic ganglia of rats with chronic streptozotocin-induced diabetes. Brain Res. 2001, 921:256-259.
59. Schmidt R.E., Dorsey D.A., Beaudet L.N., Frederick K.E., Parvin C.A., Plurad S.B., Levisetti M.G. Non-obese diabetic mice rapidly develop dramatic sympathetic neuritic dystrophy: a new experimental model of diabetic autonomic neuropathy. Am. J. Pathol. 2003, 163:2077-2091.
60. Schmidt R.E., Green K.G., Feng D., Dorsey D.A., Parvin C.A., Lee J.M., Xiao Q., Brines M. Erythropoietin and its carbamylated derivative prevent the development of experimental diabetic autonomic neuropathy in STZ-induced diabetic NOD-SCID mice. Exp. Neurol. 2008, 209:161-170.
61. Akita) diabetic mouse sympathetic ganglia. Exp. Neurol. 2009, 216:207-218.
62. Schmidt R.E., Plurad S.B. Ultrastructural and biochemical characterization of autonomic neuropathy in rats with chronic streptozotocin diabetes. J. Neuropathol. Exp. Neurol. 1986, 45:525-544.
63. Schmidt R.E., Plurad S.B., Parvin C.A., Roth K.A. Effect of diabetes and aging on human sympathetic autonomic ganglia. Am. J. Pathol. 1993, 143:143-153.
64. Schmidt R.E., Plurad D.A., Plurad S.B., Cogswell B.E., Diani A.R., Roth K.A. Ultrastructural and immunohistochemical characterization of autonomic neuropathy in genetically diabetic Chinese hamsters. Lab. Invest. 1989, 61:77-92.
65. Schmidt R.E., Summerfield A.L., Hickey W.F. Ultrastructural and immunohistologic characterization of guanethidine-induced destruction of peripheral sympathetic neurons. J. Neuropathol. Exp. Neurol. 1990, 49:150-167.
66. Schmidt R.E., Plurad S.B., Olack B.J., Scharp D.W. The effect of pancreatic islet transplantation and insulin therapy on experimental diabetic autonomic neuropathy. Diabetes 1983, 32:532-540.
67. Schmidt R.E., Dorsey D.A., Beaudet L.N., Plurad S.B., Parvin C.A., Miller M.S. Insulin-like growth factor I reverses experimental diabetic autonomic neuropathy. Am. J. Pathol. 1999, 155:1651-1660.
68. Silos-Santiago I., Molliver D.C., Ozaki S., Smeyne R.J., Fagan A.M., Barbacid M., Snider W.D. Non-TrkA-expressing small DRG neurons are lost in TrkA deficient mice. J. Neurosci. 1995, 15:5929-5942.
69. Singh A.K., Szczech L., Tang K.L., Barnhart H., Sapp S., Wolfson M., Reddan D. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 2006, 355:2085-2098.
70. Sirén A.-L., Fratelli M., Brines M., Goemans C., Casagrande S., Lewczuk P., Keenan S., Gleiter C., Pasquali C., Capobianco A., Mennini T., Heumann R., Cerami A., Ehrenreich H., Ghezzi P. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:4044-4049.
71. Sowade B., Sowade O., Mocks J., Franke W., Warnke H. The safety of treatment with recombinant human erythropoietin in clinical use: a review of controlled studies. Int. J. Mol. Med. 1998, 1:303-314.
72. Spallone V., Maiello M.R., Kurukulasuriya N., Barini A., Lovecchio M., Tartaglione R., Mennuni G., Menzinger G. Does autonomic neuropathy play a role in erythropoietin regulation in non-proteinuric Type 2 diabetic patients?. Diabet. Med. 2004, 21:1174-1180.
73. Spivak J.L. Erythropoietin use and abuse: when physiology and pharmacology collide. Adv. Exp. Med. Biol. 2001, 502:207-224.
74. Steensma D.P., Loprinzi C.L. Erythropoietin use in cancer patients: a matter of life and death?. J. Clin. Oncol. 2005, 23:5865-5868.
75. Tam J., Diamond J., Maysinger D. Dual-action peptides: a new strategy in the treatment of diabetes-associated neuropathy. Drug Discov. Today 2006, 11:254-260.
76. Winkler A.S., Landau S., Watkins P., Chaudhuri K.R. Observations on haematological and cardiovascular effects of erythropoietin treatment in multiple system atrophy with sympathetic failure. Clin. Auton. Res. 2002, 12:203-206.
77. Yagihashi S., Sima A.A. Diabetic autonomic neuropathy. The distribution of structural changes in sympathetic nerves of the BB rat. Am. J. Pathol. 1985, 121:138-147.
78. Yoshioka M., Kayo T., Ikeda T., Koizumi A. A novel locus, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese C57BL/6 (Akita) mutant mice. Diabetes 1997, 46:887-894.
79. Yuan H., Gerencser A.A., Liot G., Lipton S.A., Ellisman M., Perkins G.A., Bossy-Wetzel E. Mitochondrial fission is an upstream and required event for bax foci formation in response to nitric oxide in cortical neurons. Cell Death Differ. 2007, 14:462-471.
80. Zochodne D.W., Ramji N., Toth C. Neuronal targeting in diabetes mellitus: a story of sensory neurons and motor neurons. Neuroscientist 2008, 14:311-318.